Addiction medicine

Danielle O'Neal
Clinical Articles iconClinical Articles

When are they useful and how can you minimise risk of dependence

Danielle O'Neal
Clinical Articles iconClinical Articles

A far cry from the facetious stigma as ‘mother’s little helper’ in the 1960s; problematic use of benzodiazepines is now largely an “indiscriminate” problem occurring across most sociodemographics, says Dr Adam Straub, addiction medicine physician and general physician. 

Dr Adam Straub
Podcasts iconPodcasts

Dr Adam Straub presents the current state of play for identifying, diagnosing and treating opioid dependence in primary care.

Expert/s: Dr Adam Straub
Helen Tobler
Clinical Articles iconClinical Articles

Two options are now widely available in primary care, reducing stigma and improving convenience...

Expert/s: Helen Tobler
Dr Adam Straub
Podcasts iconPodcasts

Dr Adam Straub addresses benzo dependency with real-world advice and evidence-based recommendations

Expert/s: Dr Adam Straub
Lynnette Hoffman
Clinical Articles iconClinical Articles

Three experts explain the evidence and practical implications for GPs...

Ben Falkenmire
Clinical Articles iconClinical Articles

Dr Christine Read used her GP skills to realise her lifelong painting dream…

Expert/s: Ben Falkenmire
Mark Horowitz
Clinical Articles iconClinical Articles

Misinformation about antidepressants and is probably fuelling their rise in use. Chief among these false ideas are

Prof Benjamin Land
Clinical Articles iconClinical Articles

Drug overdose deaths from opioids continue to rise in the U.S. as a result of both the misuse of prescription opioids and the illicit drug market

University of Washington Health Sciences/UW Medicine
Clinical Articles iconClinical Articles

It takes a supreme effort of will to overcome an addiction, but even more so to avoid relapse. The effect of relapse can hugely effect quality of life or even prove fatal. To help give recovering addicts a fighting chance, researchers at University of Washington have been studying whether changing the activity of neurons in the nucleus accumbens, the region of the brain that regulates addictive behaviour, can help to prevent relapse. They achieved this targeted change in brain activity using chemogenetic receptors in a study conducted on rats who had been exposed to heroin.

Dr Linda Calabresi
Clinical Articles iconClinical Articles

It’s a controversial topic here in Australia. But a new UK study, just published in the New England Journal of Medicine, gives strong support the role of e-cigarettes as a smoking cessation therapy. The randomised controlled trial of almost 900 adult smokers wanting to quit found the one-year abstinence rate was 18% among the e-cigarette users compared to 9.9% among those who were randomised to receive nicotine replacement therapy. Much of the difference could be attributed to adherence to the assigned product. After 12 months, 80% of the e-cigarette group were still using the device whereas only 9% of the alternative group were still taking their nicotine replacement therapy despite being able to choose between the patch, gum, lozenge, nasal spray, inhalator, mouth spray, mouth strip, and microtabs (or any combination of these). Participants in both groups underwent the same multi-session behavioural support as per best practice guidelines. This study provides some of the strongest evidence to date that e-cigarettes are significantly better than nicotine replacement therapy in helping people quit smoking, the study authors suggest. “This is particularly noteworthy given that nicotine replacement was used under expert guidance, with access to the full range of nicotine-replacement products and with 88.1% of participants using combination treatments,” they said. The researchers suggested e-cigarettes had better adherence rate because they were more effective at reducing the symptoms of withdrawal when quitting smoking, because the refillable devices are better at delivering nicotine compared with options such as gum or patches. They also suggest the nicotine dose provided by e-cigarettes was easier to tailor to individual needs than other replacement options. And even though people using the e-cigarettes were more likely to get mouth or throat irritation, this side effect was generally mild and tolerable especially compared to withdrawal symptoms such as constipation, mouth ulcers and weight gain. In general, the researchers claim replacing cigarettes with e-cigarettes is a definite positive in terms of health outcomes and much better than other nicotine replacement options, but they suggest the high rate of adherence in the e-cigarette group may have some negative connotations. “This can be seen as problematic if e-cigarette use for a year signals ongoing long-term use, which may pose as-yet-unknown health risks,” they said. As an accompanying editorial points out, fundamentally nicotine is highly addictive. While electronic cigarettes have been proven to be a great tool in helping people get off normal cigarettes, there may be an issue if non-smokers, especially teenagers take up vaping, making them vulnerable to becoming smokers further down the track. “The cigarette company may well see e-cigarettes as addictive bait that will lead young people toward smoking,” the US editorial authors suggest. They suggest this potential problem could be relatively easily averted by ensuring e-cigarettes aren’t manipulated to enhance their appeal, specifically the authorities should not allow the manufacture of flavoured nicotine products. However, they too acknowledge e-cigarettes have a significant role to play in solving this public health problem – ‘by helping people who are users of combustible tobacco products stop smoking by switching to vaping.’

References:

Hajek P, Phillips-Waller A, Przulj D, Pesola F, Smith KM, Bisal N, et al. A Randomized Trial of E-Cigarettes versus Nicotine-Replacement Therapy.  N Engl J Med. 2019 Jan 30;  DOI: 10.1056/NEJMoa1808779 [Epub ahead of print] Drazen JM, Morrissey S, Campion EW. The Dangerous Flavors of E-Cigarettes. N Engl J Med. 2019 Jan 30. DOI: 10.1056/NEJMe1900484 [Epub ahead of print]